Click here for important packaging information, and see below video for additional guidance on packaging.
Casirivimab and imdevimab are both sterile, preservative-free, clear to slightly opalescent and colorless to pale yellow solutions, supplied each as a single-dose vial to be administered together in a single IV infusion after dilution. Product is shipped refrigerated (2-8° C) to the administration site by AmerisourceBergen Corporation.
New REGEN-COV dose packs are now available.
Each REGEN-COV dose pack contains sufficient number of vials of casirivimab and imdevimab to prepare one treatment dose of REGEN-COV.
1 vial of casirivimab
11.1mL
NDC 61755-024-01
1 vial of Imdevimab
11.1mL
NDC 61755-025-01
1 vial of casirivimab
11.1mL
NDC 61755-024-01
4 vial of Imdevimab
2.5mL
NDC 61755-027-01
4 vial of casirivimab
2.5mL
NDC 61755-026-01
4 vial of Imdevimab
2.5mL
NDC 61755-027-01
4 vials of casirivimab
2.5mL
NDC 61755-026-01
1 vial of Imdevimab
11.1mL
NDC 61755-025-01
Back
PreviousNext
NextAntibody | Concentration | Package Size | NDC Number |
---|---|---|---|
Casirivimab (REGN10933) |
1332 mg/11.1 mL (120 mg/mL) |
1 vial per carton | 61755-024-01 |
300 mg/2.5 mL (120 mg/mL) |
1 vial per carton | 61755-026-01 | |
Imdevimab (REGN10987) |
1332 mg/11.1 mL (120 mg/mL) |
1 vial per carton | 61755-025-01 |
300 mg/2.5 mL (120 mg/mL) |
1 vial per carton | 61755-027-01 |
Concentration | |
---|---|
Casirivimab (REGN10933) |
1332 mg/11.1 mL (120 mg/mL) |
300 mg/2.5 mL (120 mg/mL) |
|
Imdevimab (REGN10987) |
1332 mg/11.1 mL (120 mg/mL) |
300 mg/2.5 mL (120 mg/mL) |
|
Package Size | |
Casirivimab (REGN10933) |
1 vial per carton |
Imdevimab (REGN10987) |
1 vial per carton |
NDC Number | |
Casirivimab (REGN10933) |
61755-024-01 |
61755-026-01 | |
Imdevimab (REGN10987) |
61755-025-01 |
61755-027-01 |
Explore more helpful information about REGEN-COV.
The development and manufacturing of casirivimab and imdevimab has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) under OT number: HHSO100201700020C.
REGEN-COV (casirivimab with imdevimab) is an unapproved investigational therapy, and there are limited clinical data available. Serious and unexpected adverse events may occur that have not been previously reported with REGEN-COV use.
REGEN-COV (casirivimab with imdevimab to be administered together) is authorized for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. [see Limitations of Authorized Use]
Limitations of Authorized Use:
Definition of High Risk Patients
High risk is defined as patients who meet at least one of the following criteria:
Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies. Healthcare providers should review the Antiviral Resistance information in Section 15 of the Fact Sheet for Healthcare Providers for details regarding specific variants and resistance, and refer to the CDC website as well as information from state and local health authorities regarding reports of viral variants of importance in their region to guide treatment decisions.
1. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
REGEN-COV (casirivimab with imdevimab) is an unapproved investigational therapy, and there are limited clinical data available. Serious and unexpected adverse events may occur that have not been previously reported with REGEN-COV use.
READ MORE
You are now leaving REGENCOV.com
Please note: By clicking on this link, you will be leaving this Regeneron-hosted US website and going to another independent website. Regeneron provides these links as a service to its website visitors and users; however, it takes no responsibility for the information on any website but its own.
This website www.regencov.com (the "site") uses "cookies". Cookies are small text files which are automatically placed on your computer by the internet browser when you visit the Site. A cookie can, amongst other things, track the web pages you visit and the options you use. Regeneron Pharmaceuticals, Inc. and its affiliates use this data to make the Site more user-friendly and efficient. We use Google Analytics cookie service to track and obtain reports on how visitors are using the Site. The information obtained with this cookie, which includes the IP address of your computer, will be transmitted to and stored by Google on servers in the United States. Google may share that information with third parties if Google is obliged to do so by law or to the extent such third parties are processing this information on behalf of Google. Regeneron has no influence on such use.
REGN10933
2.5 mL
11.1 mL
REGN10987
2.5 mL
11.1 mL